Autoimmune uveitis Market: Epidemiology, Therapies, Companies, DelveInsight | Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc.

The Autoimmune Uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Autoimmune Uveitis market size from 2020 to 2034. The Autoimmune Uveitis market report also covers current Autoimmune Uveitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autoimmune Uveitis market.

Therapies for autoimmune uveitis, including YUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and others, are projected to drive growth in the autoimmune uveitis market in the coming years.

DelveInsight has released a new report titled "Autoimmune Uveitis - Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into autoimmune uveitis, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover more about autoimmune uveitis, treatment algorithms, therapies @ https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Autoimmune uveitis Market Report:

*
The Autoimmune Uveitis market across the 7MM was valued at approximately USD 1.29 billion in 2022 and is projected to grow significantly by 2034 at a strong CAGR. Among these regions, the US led the market with around USD 840 million in 2022, while Italy recorded the lowest value at USD 39 million; both are expected to expand further by 2034.

*
The US accounted for the largest patient pool, followed by the EU4 countries, the UK, and Japan. Variations in autoimmune uveitis subtypes influence treatment choices, outcomes, and healthcare resource planning. Anterior noninfectious uveitis (aNIU) represented the highest number of diagnosed prevalent cases, followed by pan-uveitis and posterior uveitis across the 7MM.

*
At present, HUMIRA remains the only FDA-approved biologic for autoimmune uveitis. Biologics dominated the market in 2022, contributing nearly USD 960 million across the 7MM. Future growth is expected to be driven by pipeline therapies such as TRS01, OCS-02, and EYS606.

*
In Europe, the EU4 countries and the UK together reported 0.26 million diagnosed cases in 2022, with Germany leading at 73,000 cases. Japan accounted for about 17% of the total diagnosed population in the 7MM, representing 0.1 million cases that year.

*
Key players advancing new therapies for autoimmune uveitis include Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, and others. Notable emerging treatment options include YUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and additional pipeline candidates.

Key benefits of the Autoimmune uveitis market report:

*
Autoimmune uveitis market report covers a descriptive overview and comprehensive insight of the Autoimmune uveitis Epidemiology and Autoimmune uveitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

*
The Autoimmune uveitis market report provides insights on the current and emerging therapies.

*
Autoimmune uveitis market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Autoimmune uveitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autoimmune uveitis market.

Got queries? Click here to know more about the Autoimmune uveitis Market Landscape https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Autoimmune uveitis Overview

Autoimmune uveitis is an inflammatory disorder that primarily targets the uveal structures of the eye, arising either from an autoimmune response against self-antigens or from an innate inflammatory reaction triggered by external factors. It may present as an isolated ocular condition or in association with systemic autoimmune or autoinflammatory diseases.

While it mainly affects the uvea, other ocular tissues can also be involved. Uveitis is generally classified as infectious or noninfectious, with noninfectious uveitis (NIU) either linked to systemic autoimmune disorders or restricted to the eye. NIU symptoms often include eye pain, redness, tearing, and sensitivity to light (photophobia). Broader uveitis symptoms may also present as blurred vision, floaters, headaches, and conjunctival injection, though in some pediatric cases, the condition may be asymptomatic.

Autoimmune uveitis Market Outlook

Managing noninfectious uveitis (NIU) and other autoimmune disorders is often complex, requiring more than simply targeting a single pathway. In recent years, however, advances in biologic therapies-such as HUMIRA-have provided new targeted treatment options, with some specifically approved for NIU.

Local therapies for NIU most commonly involve corticosteroids, though agents like sirolimus and methotrexate have also been evaluated for intraocular delivery. Currently approved local treatments include topical steroids, short-acting intra- or periocular steroids such as triamcinolone acetonide, and sustained-release intravitreal implants like OZURDEX and YUTIQ.

The pipeline for autoimmune uveitis continues to expand, with promising candidates such as TRS01 eye drops for noninfectious anterior uveitis, OCS-02 for acute anterior uveitis, and EYS606-a combination product for chronic noninfectious uveitis-anticipated to drive growth in the market.

Explore how the autoimmune uveitis market is rising @ https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Autoimmune uveitis marketed drugs:

*
YUTIQ: Eyepoint Pharmaceuticals

*
HUMIRA (Adalimumab): AbbVie Inc.

Autoimmune uveitis emerging drugs:

*
TRS01: Tarsier Pharma

*
OCS-02: Oculis Pharma

Scope of the Autoimmune uveitis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Autoimmune uveitis Companies: Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others

*
Key Autoimmune uveitis Therapies: IYUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and others

*
Autoimmune uveitis Therapeutic Assessment: Autoimmune uveitis current marketed and Autoimmune uveitis emerging therapies

*
Autoimmune uveitis Market Dynamics: Autoimmune uveitis market drivers and Autoimmune uveitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Autoimmune uveitis Unmet Needs, KOL's views, Analyst's views, Autoimmune uveitis Market Access and Reimbursement

Request for a sample report @ https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Autoimmune uveitis Patient Share (%) Overview at a Glance

5. Autoimmune uveitis Market Overview at a Glance

6. Autoimmune uveitis Disease Background and Overview

7. Autoimmune uveitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Autoimmune uveitis

9. Autoimmune uveitis Current Treatment and Medical Practices

10. Unmet Needs

11. Autoimmune uveitis Emerging Therapies

12. Autoimmune uveitis Market Outlook

13. Country-Wise Autoimmune uveitis Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Autoimmune uveitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Autoimmune uveitis Market Outlook 2034 https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Autoimmune uveitis Pipeline Insights, DelveInsight

"Autoimmune uveitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune uveitis market. A detailed picture of the Autoimmune uveitis pipeline landscape is provided, which includes the disease overview and Autoimmune uveitis treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=autoimmune-uveitis-market-epidemiology-therapies-companies-delveinsight-tarsier-pharma-eli-lilly-and-company-oculis-pharma-eyevensys-priovant-therapeutics-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.